Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress

MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer

Relay Therapeutics Strengthens Leadership Team With Key Additions In R&D, Legal, And Finance

Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting

GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.

U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome

Foundation Medicine Announces Commercial Availability of FoundationOne CDxâ„¢, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagnostics

bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

Editas Medicine Names James C. Mullen as Chairman of the Board of Directors

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-mediated Diseases

Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion

Goldfinch Bio to Present at BioCentury’s Future Leaders in Biotech Industry Conference

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call

Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018

Foundation Medicine Announces Final National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS), Including Coverage for FoundationOne CDxâ„¢ Across All Solid Tumors

Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval for FoundationOne CDxâ„¢ in Japan

Fulcrum Therapeutics to Present at BioCentury’s Future Leaders in the Biotech Industry Conference

Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

TARIS® Announces Research Collaboration Focused on Natural History of Muscle Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy

Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018

TARIS® Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy

Foundation Medicine and Guardant Health Agree to Resolve False Advertising Lawsuit

Goldfinch Bio Bolsters Leadership Team by Appointing Dr. Peter Mundel as Chief Scientific Officer and Electing Dr. Frank Maddux to Board of Directors

Warp Drive Bio to Present at Cowen and Company 38th Annual Health Care Conference

Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer

Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

TARIS® to Present at Cowen Health Care Conference

Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson's Disease

Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock

Tango Therapeutics Expands Board of Directors with the Addition of Leading Oncology Experts with Deep Experience in Targeted and Personalized Therapies

MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires

Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Foundation Medicine to Present at Cowen and Company's 38th Annual Healthcare Conference

Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update

Foundation Medicine Announces 2017 Fourth Quarter and Year-End Results, Recent Highlights and 2018 Outlook

Relay Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference

Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March

Zafgen to Present at Cowen 38th Annual Health Care Conference